Fenofibrate (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Fenofibrate" in English language version.

refsWebsite

Global rank English rank

29nih.gov

4^th place

18doi.org

2^nd place

6semanticscholar.org

11^th place

8^th place

2tga.gov.au

3,984^th place

2,622^nd place

2drugs.com

399^th place

333^rd place

2clincalc.com

3,912^th place

2,496^th place

2web.archive.org

1^st place

1medicines.org.uk

3,823^rd place

2,387^th place

1books.google.com

3^rd place

1rxabbott.com

low place

1s3.amazonaws.com

1,540^th place

958^th place

1fda.gov

447^th place

338^th place

1psu.edu

207^th place

136^th place

1harvard.edu

18^th place

17^th place

1fdanews.com

low place

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 474. ISBN 9783527607495.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Fenofibrate Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

doi.org

Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, et al. (April 2010). "Effects of combination lipid therapy in type 2 diabetes mellitus". The New England Journal of Medicine. 362 (17): 1563–1574. doi:10.1056/NEJMoa1001282. PMC 2879499. PMID 20228404.{{cite journal}}: CS1 maint: overridden setting (link)
Kim NH, Han KH, Choi J, Lee J, Kim SG (September 2019). "Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study". BMJ. 366: l5125. doi:10.1136/bmj.l5125. PMC 6763755. PMID 31562117. S2CID 203580658.
Wong TY, Simó R, Mitchell P (July 2012). "Fenofibrate - a potential systemic treatment for diabetic retinopathy?". American Journal of Ophthalmology. 154 (1): 6–12. doi:10.1016/j.ajo.2012.03.013. PMID 22709833.
Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. (November 2007). "Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial". Lancet. 370 (9600): 1687–1697. doi:10.1016/S0140-6736(07)61607-9. PMID 17988728. S2CID 30479730.{{cite journal}}: CS1 maint: overridden setting (link)
Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, et al. (December 2014). "The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study". Ophthalmology. 121 (12): 2443–2451. doi:10.1016/j.ophtha.2014.07.019. PMC 4252767. PMID 25172198.{{cite journal}}: CS1 maint: overridden setting (link)
Fazio S (June 2009). "More clinical lessons from the FIELD study". Cardiovascular Drugs and Therapy. 23 (3): 235–241. doi:10.1007/s10557-008-6160-5. PMID 19160032. S2CID 7987660.
Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, et al. (April 2017). "Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes". JAMA Cardiology. 2 (4): 370–380. doi:10.1001/jamacardio.2016.4828. PMC 5470410. PMID 28030716.{{cite journal}}: CS1 maint: overridden setting (link)
Kim NH, Han KH, Choi J, Lee J, Kim SG (September 2019). "Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study". BMJ. 366: l5125. doi:10.1136/bmj.l5125. PMC 6763755. PMID 31562117.
Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, et al. (May 2009). "Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial". Lancet. 373 (9677): 1780–1788. doi:10.1016/S0140-6736(09)60698-X. PMC 2687887. PMID 19465233.{{cite journal}}: CS1 maint: overridden setting (link)
Steiner G (October 2009). "How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD". Cardiovascular Drugs and Therapy. 23 (5): 403–408. doi:10.1007/s10557-009-6190-7. PMID 19757004. S2CID 12747599.
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. (October 2012). "2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia". Arthritis Care & Research. 64 (10): 1431–1446. doi:10.1002/acr.21772. PMC 3683400. PMID 23024028.{{cite journal}}: CS1 maint: overridden setting (link)
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. (June 2014). "2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. 129 (25 Suppl 2): S1-45. doi:10.1161/01.cir.0000437738.63853.7a. PMID 24222016.{{cite journal}}: CS1 maint: overridden setting (link)
Wierzbicki AS, Mikhailidis DP, Wray R, Schacter M, Cramb R, Simpson WG, et al. (2003). "Statin-fibrate combination: therapy for hyperlipidemia: a review". Current Medical Research and Opinion. 19 (3): 155–168. doi:10.1185/030079903125001668. PMID 12814127. S2CID 35948128.
Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC (November 1998). "Mechanism of action of fibrates on lipid and lipoprotein metabolism". Circulation. 98 (19): 2088–2093. CiteSeerX 10.1.1.1004.321. doi:10.1161/01.cir.98.19.2088. PMID 9808609. S2CID 5858864.
Ling H, Luoma JT, Hilleman D (April 2013). "A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations". Cardiology Research. 4 (2): 47–55. doi:10.4021/cr270w. PMC 5358213. PMID 28352420.
Alagona P (May 2010). "Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia". Vascular Health and Risk Management. 6: 351–362. doi:10.2147/vhrm.s6714. PMC 2879297. PMID 20531954.
Black GP, He G, Denison MS, Young TM (May 2021). "Using Estrogenic Activity and Nontargeted Chemical Analysis to Identify Contaminants in Sewage Sludge". Environmental Science & Technology. 55 (10): 6729–6739. Bibcode:2021EnST...55.6729B. doi:10.1021/acs.est.0c07846. PMC 8378343. PMID 33909413.
Lalloyer F, Staels B (May 2010). "Fibrates, glitazones, and peroxisome proliferator-activated receptors". Arteriosclerosis, Thrombosis, and Vascular Biology. 30 (5): 894–899. doi:10.1161/ATVBAHA.108.179689. PMC 2997800. PMID 20393155.

drugs.com

"Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
"Fenofibrate Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.

fda.gov

accessdata.fda.gov

Fenofibric Acid FDA Label Prescribing Information"FDA Label Information" (PDF). FDA.

fdanews.com

"Abbott's request to dismiss the antitrust charge over Tricor was rejected". FDANews, Drug Daily Bulletin. 1 June 2006.

harvard.edu

ui.adsabs.harvard.edu

Black GP, He G, Denison MS, Young TM (May 2021). "Using Estrogenic Activity and Nontargeted Chemical Analysis to Identify Contaminants in Sewage Sludge". Environmental Science & Technology. 55 (10): 6729–6739. Bibcode:2021EnST...55.6729B. doi:10.1021/acs.est.0c07846. PMC 8378343. PMID 33909413.

medicines.org.uk

"Fenofibrate 267mg Capsules - Summary of Product Characteristics (SmPC)". (emc). 12 February 2020. Retrieved 13 April 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, et al. (April 2010). "Effects of combination lipid therapy in type 2 diabetes mellitus". The New England Journal of Medicine. 362 (17): 1563–1574. doi:10.1056/NEJMoa1001282. PMC 2879499. PMID 20228404.{{cite journal}}: CS1 maint: overridden setting (link)
Kim NH, Han KH, Choi J, Lee J, Kim SG (September 2019). "Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study". BMJ. 366: l5125. doi:10.1136/bmj.l5125. PMC 6763755. PMID 31562117. S2CID 203580658.
Wong TY, Simó R, Mitchell P (July 2012). "Fenofibrate - a potential systemic treatment for diabetic retinopathy?". American Journal of Ophthalmology. 154 (1): 6–12. doi:10.1016/j.ajo.2012.03.013. PMID 22709833.
Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. (November 2007). "Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial". Lancet. 370 (9600): 1687–1697. doi:10.1016/S0140-6736(07)61607-9. PMID 17988728. S2CID 30479730.{{cite journal}}: CS1 maint: overridden setting (link)
Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, et al. (December 2014). "The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study". Ophthalmology. 121 (12): 2443–2451. doi:10.1016/j.ophtha.2014.07.019. PMC 4252767. PMID 25172198.{{cite journal}}: CS1 maint: overridden setting (link)
Fazio S (June 2009). "More clinical lessons from the FIELD study". Cardiovascular Drugs and Therapy. 23 (3): 235–241. doi:10.1007/s10557-008-6160-5. PMID 19160032. S2CID 7987660.
Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, et al. (April 2017). "Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes". JAMA Cardiology. 2 (4): 370–380. doi:10.1001/jamacardio.2016.4828. PMC 5470410. PMID 28030716.{{cite journal}}: CS1 maint: overridden setting (link)
Kim NH, Han KH, Choi J, Lee J, Kim SG (September 2019). "Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study". BMJ. 366: l5125. doi:10.1136/bmj.l5125. PMC 6763755. PMID 31562117.
Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, et al. (May 2009). "Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial". Lancet. 373 (9677): 1780–1788. doi:10.1016/S0140-6736(09)60698-X. PMC 2687887. PMID 19465233.{{cite journal}}: CS1 maint: overridden setting (link)
Steiner G (October 2009). "How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD". Cardiovascular Drugs and Therapy. 23 (5): 403–408. doi:10.1007/s10557-009-6190-7. PMID 19757004. S2CID 12747599.
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. (October 2012). "2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia". Arthritis Care & Research. 64 (10): 1431–1446. doi:10.1002/acr.21772. PMC 3683400. PMID 23024028.{{cite journal}}: CS1 maint: overridden setting (link)
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. (June 2014). "2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. 129 (25 Suppl 2): S1-45. doi:10.1161/01.cir.0000437738.63853.7a. PMID 24222016.{{cite journal}}: CS1 maint: overridden setting (link)
Wierzbicki AS, Mikhailidis DP, Wray R, Schacter M, Cramb R, Simpson WG, et al. (2003). "Statin-fibrate combination: therapy for hyperlipidemia: a review". Current Medical Research and Opinion. 19 (3): 155–168. doi:10.1185/030079903125001668. PMID 12814127. S2CID 35948128.
Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC (November 1998). "Mechanism of action of fibrates on lipid and lipoprotein metabolism". Circulation. 98 (19): 2088–2093. CiteSeerX 10.1.1.1004.321. doi:10.1161/01.cir.98.19.2088. PMID 9808609. S2CID 5858864.
Ling H, Luoma JT, Hilleman D (April 2013). "A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations". Cardiology Research. 4 (2): 47–55. doi:10.4021/cr270w. PMC 5358213. PMID 28352420.
Alagona P (May 2010). "Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia". Vascular Health and Risk Management. 6: 351–362. doi:10.2147/vhrm.s6714. PMC 2879297. PMID 20531954.
Black GP, He G, Denison MS, Young TM (May 2021). "Using Estrogenic Activity and Nontargeted Chemical Analysis to Identify Contaminants in Sewage Sludge". Environmental Science & Technology. 55 (10): 6729–6739. Bibcode:2021EnST...55.6729B. doi:10.1021/acs.est.0c07846. PMC 8378343. PMID 33909413.
Lalloyer F, Staels B (May 2010). "Fibrates, glitazones, and peroxisome proliferator-activated receptors". Arteriosclerosis, Thrombosis, and Vascular Biology. 30 (5): 894–899. doi:10.1161/ATVBAHA.108.179689. PMC 2997800. PMID 20393155.

ncbi.nlm.nih.gov

Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, et al. (April 2010). "Effects of combination lipid therapy in type 2 diabetes mellitus". The New England Journal of Medicine. 362 (17): 1563–1574. doi:10.1056/NEJMoa1001282. PMC 2879499. PMID 20228404.{{cite journal}}: CS1 maint: overridden setting (link)
Kim NH, Han KH, Choi J, Lee J, Kim SG (September 2019). "Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study". BMJ. 366: l5125. doi:10.1136/bmj.l5125. PMC 6763755. PMID 31562117. S2CID 203580658.
Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, et al. (December 2014). "The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study". Ophthalmology. 121 (12): 2443–2451. doi:10.1016/j.ophtha.2014.07.019. PMC 4252767. PMID 25172198.{{cite journal}}: CS1 maint: overridden setting (link)
Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, et al. (April 2017). "Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes". JAMA Cardiology. 2 (4): 370–380. doi:10.1001/jamacardio.2016.4828. PMC 5470410. PMID 28030716.{{cite journal}}: CS1 maint: overridden setting (link)
Kim NH, Han KH, Choi J, Lee J, Kim SG (September 2019). "Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study". BMJ. 366: l5125. doi:10.1136/bmj.l5125. PMC 6763755. PMID 31562117.
Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, et al. (May 2009). "Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial". Lancet. 373 (9677): 1780–1788. doi:10.1016/S0140-6736(09)60698-X. PMC 2687887. PMID 19465233.{{cite journal}}: CS1 maint: overridden setting (link)
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. (October 2012). "2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia". Arthritis Care & Research. 64 (10): 1431–1446. doi:10.1002/acr.21772. PMC 3683400. PMID 23024028.{{cite journal}}: CS1 maint: overridden setting (link)
Ling H, Luoma JT, Hilleman D (April 2013). "A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations". Cardiology Research. 4 (2): 47–55. doi:10.4021/cr270w. PMC 5358213. PMID 28352420.
Alagona P (May 2010). "Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia". Vascular Health and Risk Management. 6: 351–362. doi:10.2147/vhrm.s6714. PMC 2879297. PMID 20531954.
Black GP, He G, Denison MS, Young TM (May 2021). "Using Estrogenic Activity and Nontargeted Chemical Analysis to Identify Contaminants in Sewage Sludge". Environmental Science & Technology. 55 (10): 6729–6739. Bibcode:2021EnST...55.6729B. doi:10.1021/acs.est.0c07846. PMC 8378343. PMID 33909413.
Lalloyer F, Staels B (May 2010). "Fibrates, glitazones, and peroxisome proliferator-activated receptors". Arteriosclerosis, Thrombosis, and Vascular Biology. 30 (5): 894–899. doi:10.1161/ATVBAHA.108.179689. PMC 2997800. PMID 20393155.

psu.edu

citeseerx.ist.psu.edu

Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC (November 1998). "Mechanism of action of fibrates on lipid and lipoprotein metabolism". Circulation. 98 (19): 2088–2093. CiteSeerX 10.1.1.1004.321. doi:10.1161/01.cir.98.19.2088. PMID 9808609. S2CID 5858864.

rxabbott.com

"TRICOR (fenofibrate) Package Insert" (PDF). Abbot Laboratories. October 2010.

s3.amazonaws.com

"AbbVie Inc. et al; Withdrawal of Approval of Indications Related to the Coadministration With Statins in Applications for Niacin Extended-Release Tablets and Fenofibric Acid Delayed- Release Capsules" (PDF). Food and Drug Administration. 18 April 2016.

semanticscholar.org

api.semanticscholar.org

Kim NH, Han KH, Choi J, Lee J, Kim SG (September 2019). "Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study". BMJ. 366: l5125. doi:10.1136/bmj.l5125. PMC 6763755. PMID 31562117. S2CID 203580658.
Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. (November 2007). "Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial". Lancet. 370 (9600): 1687–1697. doi:10.1016/S0140-6736(07)61607-9. PMID 17988728. S2CID 30479730.{{cite journal}}: CS1 maint: overridden setting (link)
Fazio S (June 2009). "More clinical lessons from the FIELD study". Cardiovascular Drugs and Therapy. 23 (3): 235–241. doi:10.1007/s10557-008-6160-5. PMID 19160032. S2CID 7987660.
Steiner G (October 2009). "How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD". Cardiovascular Drugs and Therapy. 23 (5): 403–408. doi:10.1007/s10557-009-6190-7. PMID 19757004. S2CID 12747599.
Wierzbicki AS, Mikhailidis DP, Wray R, Schacter M, Cramb R, Simpson WG, et al. (2003). "Statin-fibrate combination: therapy for hyperlipidemia: a review". Current Medical Research and Opinion. 19 (3): 155–168. doi:10.1185/030079903125001668. PMID 12814127. S2CID 35948128.
Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC (November 1998). "Mechanism of action of fibrates on lipid and lipoprotein metabolism". Circulation. 98 (19): 2088–2093. CiteSeerX 10.1.1.1004.321. doi:10.1161/01.cir.98.19.2088. PMID 9808609. S2CID 5858864.

tga.gov.au

"Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
"Australian Public Assessment Report for fenofibrate". TGA. Archived from the original on 29 June 2015. Retrieved 27 June 2015.

web.archive.org

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Australian Public Assessment Report for fenofibrate". TGA. Archived from the original on 29 June 2015. Retrieved 27 June 2015.